Enzo Biochem to Announce Third Quarter 2020 Financial Results on Monday June 8, 2020

Nachrichtenquelle: globenewswire
03.06.2020, 22:05  |  118   |   |   

NEW YORK, NY, June 03, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc.  (NYSE: ENZ) a leading biosciences and diagnostics company, today announced that it will release its third quarter 2020 financial results after the market closes on Monday June 8, 2020. The company’s President Barry Weiner and Chief Financial Officer David Bench will host a conference call for the investment community the same day at 5:00 PM ET (2:00 PM PT) to discuss the results and answer questions.

The call can be accessed through a live audio webcast and through a live conference call by dialing +1 323-794-2590 using the conference code 9751599. An archived webcast of the conference call will also be available on the Enzo Investor Relations website following the call.

About Enzo Biochem
 

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

###

Contact:

For Enzo Biochem, Inc.

David Bench, CFO
212-583-0100
dbench@enzo.com

Investors/Media:

Melanie Solomon
The Blueshirt Group
415-217-4964
melanie@blueshirtgroup.com

Steve Anreder
Anreder & Company
212-532-3232
Steven.anreder@anreder.com


Enzo Biochem Aktie jetzt ab 0€ handeln - auf Smartbroker.de



Diesen Artikel teilen
Wertpapier

Mehr zum Thema
Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.
5GK+S


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel